Major Depressive Disorder Clinical Trial
Official title:
A Culturally Adapted Depression Intervention for African American Adults
Primary Aim 1: Examine effectiveness of the Oh Happy Day Class (OHDC) compared to the Coping
With Depression (CWD)in increasing retention, adherence, engagement, satisfaction, and
treatment-seeking. The investigators hypothesize the OHDC compared to the CWD will result in
greater increases in: 1a. retention, 1b. adherence, 1c. engagement, and 1d. satisfaction at
the middle and end of the intervention, and 2.e. greater increase in treatment-seeking 3-,
6-, 9-, and 12- months post-intervention. Outcome measures: logs: attendance, homework
completion, class-participation level; Client Satisfaction Inventory; and Cornell Service
Index. Primary Aim 2: Examine effectiveness of the OHDC in reducing symptoms of depression at
the middle and immediate end of the intervention, and 3-, 6-, 9-, and 12- months
post-intervention. The investigators hypothesize the OHDC will result in greater reduction in
depressive symptoms compared to the CWD at 3-months post-intervention. Outcome measures:
Center for Epidemiologic Studies Depression Scale and Quick Inventory of Depression Symptoms.
Secondary Aim 3: Examine the effectiveness of the OHDC in improving self-reports of mental
and physical health status and reducing self-reports of perceived disability. The
investigators hypothesize the OHDC compared to the CWD will result in greater self-report of:
3a. improved mental and physical health status, and 3b. reduced self-report of disability at
the immediate end of the intervention and 3-,6-, 9-, 12- months post-intervention. Outcome
measures: SF-12 Health Survey, and World Health Organization Disability Assessment Schedule.
Public Health Impact: Based on CAI research, the OHDC has the potential to be four times more
effective than the CWD. If our hypotheses are proven, the OHDC will be the first
evidence-based culturally adapted depression intervention designed specifically for African
American men and women between the ages of 30-60.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |